Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, 450052 Zhengzhou, Henan, China.
Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, 450052 Zhengzhou, Henan, China.
Life Sci. 2021 Jul 15;277:119567. doi: 10.1016/j.lfs.2021.119567. Epub 2021 May 6.
This study aimed to evaluate the effects of Asiatic acid (AA), a naturally occurring compound of pentacyclic triterpenoid, on the pathological processes of diabetic retinopathy (DR).
SD rats were induced to develop early DR by intraperitoneal injection of STZ (60 mg/kg). Four weeks after injection, the diabetic rats were orally administrated with 37.5 mg/kg or 75 mg/kg AA every day for four weeks. The integrity of blood-retinal barrier (BRB) was measured by Evans blue staining. The polarization of microglia was determined by real-time PCR, western blot, and ELISA assays. The inner BRB (iBRB) or outer BRB (oBRB) breakdown was induced in human retinal endothelial cells or APRE19 cells through co-culture with high glucose and LPS-stimulated microglia BV2 cells. The damage to the iBRB and oBRB was measured using transendothelial/transepithelial electrical resistance (TEER/TER) and FITC-conjugated dextran cell permeability assays.
Results demonstrated that AA alleviated BRB breakdown, as evidenced by decreased protein expression of occludin, claudin-5, and ZO-1. Furthermore, AA treatment suppressed inflammation and M1 polarization, while it increased M2 polarization in the retina of DR rats. In vitro, the iBRB or oBRB breakdown was alleviated by AA. LPS-induced M1-polarization of BV2 cells under high glucose condition was also repressed through AA administration. Finally, we demonstrated that AA weakened the TLR4/MyD88/NF-κB p65 signaling pathway both in vivo and in vitro.
AA ameliorated early DR by regulating microglia polarization via the TLR4/MyD88/NF-κB p65 pathway. These data indicate that AA is a potential candidate for DR treatment.
本研究旨在评估天然存在的五环三萜化合物齐墩果酸(AA)对糖尿病视网膜病变(DR)病理过程的影响。
SD 大鼠腹腔注射 STZ(60mg/kg)诱导早期 DR。注射 4 周后,糖尿病大鼠每天口服给予 37.5mg/kg 或 75mg/kg AA,持续 4 周。通过 Evans 蓝染色测量血视网膜屏障(BRB)的完整性。通过实时 PCR、western blot 和 ELISA 测定小胶质细胞极化。通过与高糖和 LPS 刺激的小胶质细胞 BV2 细胞共培养诱导人视网膜内皮细胞或 APRE19 细胞内 BRB(iBRB)或外 BRB(oBRB)破坏。通过跨内皮/跨上皮电阻(TEER/TER)和 FITC 缀合的葡聚糖细胞通透性测定来测量 iBRB 和 oBRB 的损伤。
结果表明,AA 减轻了 BRB 破坏,表现为 occludin、claudin-5 和 ZO-1 的蛋白表达减少。此外,AA 治疗抑制了 DR 大鼠视网膜中的炎症和 M1 极化,同时增加了 M2 极化。在体外,AA 减轻了 iBRB 或 oBRB 的破坏。通过 AA 给药还抑制了高糖条件下 LPS 诱导的 BV2 细胞 M1 极化。最后,我们证明了 AA 在体内和体外均减弱了 TLR4/MyD88/NF-κB p65 信号通路。
AA 通过调节 TLR4/MyD88/NF-κB p65 通路调节小胶质细胞极化,改善早期 DR。这些数据表明,AA 是治疗 DR 的潜在候选药物。